230 related articles for article (PubMed ID: 10189564)
21. [Failure of oral hypoglycemic agents: clinical experiences in 20 years' follow-up].
Aylwin CG; López G; García de los Riós M; Vial T; Pinto JL; Ojeda A; Orellana JL
Rev Med Chil; 1988 Aug; 116(8):729-35. PubMed ID: 3255124
[No Abstract] [Full Text] [Related]
22. [Sulfonylurea compounds or biguanides in the treatment of type 2 diabetes?].
Mehnert H
Dtsch Med Wochenschr; 1989 Jul; 114(27):1086-8. PubMed ID: 2500320
[No Abstract] [Full Text] [Related]
23. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Kitaoka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
[No Abstract] [Full Text] [Related]
24. New treatments for diabetes.
Mintz ML
N Engl J Med; 2007 May; 356(21):2221-2; author reply 2222-3. PubMed ID: 17526094
[No Abstract] [Full Text] [Related]
25. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (type II DM).
Capriotti T
Medsurg Nurs; 1997 Jun; 6(3):166-9. PubMed ID: 9238992
[No Abstract] [Full Text] [Related]
26. [Triple oral therapy in type 2 diabetes].
Scheen AJ
Rev Med Suisse; 2005 Aug; 1(30):1942, 1944-6, 1948. PubMed ID: 16200937
[TBL] [Abstract][Full Text] [Related]
27. [Combination therapy with biguanides].
Sakura H
Nihon Rinsho; 2002 Oct; 60 Suppl 10():724-8. PubMed ID: 12430309
[No Abstract] [Full Text] [Related]
28. [40 years of using sulfonylurea derivatives for treatment of diabetes].
Sieradzki J
Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
[TBL] [Abstract][Full Text] [Related]
29. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
[No Abstract] [Full Text] [Related]
30. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus.
Koski RR
Diabetes Educ; 2006; 32(6):869-76. PubMed ID: 17102154
[TBL] [Abstract][Full Text] [Related]
31. Follow-up of intensive glucose control in type 2 diabetes.
Petrie JR
N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672
[No Abstract] [Full Text] [Related]
32. [Secondary failure of oral diabetes therapy].
Bergis K; Heilmann B
Fortschr Med; 1987 Feb; 105(4):64-8. PubMed ID: 3557262
[No Abstract] [Full Text] [Related]
33. Oral combination therapy for type 2 diabetes.
Charpentier G
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S70-6. PubMed ID: 12324989
[TBL] [Abstract][Full Text] [Related]
34. [Use of oral hypoglycemic agents in diabetic children].
Otto-Buczkowska E
Pol Tyg Lek; 1973; 28(24):904-7. PubMed ID: 4724902
[No Abstract] [Full Text] [Related]
35. [Biguanides in oral antidiabetic therapy: indications and limitations].
Gregorio F; Filipponi P
Medicina (Firenze); 1988; 8(3):262-8. PubMed ID: 3231038
[No Abstract] [Full Text] [Related]
36. Follow-up of intensive glucose control in type 2 diabetes.
Mühlhauser I
N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
[No Abstract] [Full Text] [Related]
37. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
[No Abstract] [Full Text] [Related]
38. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
39. Initial management of glycemia in type 2 diabetes.
Banarer S
N Engl J Med; 2003 Feb; 348(8):760-1; author reply 760-1. PubMed ID: 12594327
[No Abstract] [Full Text] [Related]
40. Mode of action of oral hypoglycemic drugs. Introductory remarks.
Fain JN
Fed Proc; 1977 Dec; 36(13):2712-3. PubMed ID: 336409
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
